Abstract Background Graphical displays and data visualization are essential components of statistical analysis that can lead to improved understanding of clinical trial adverse event (AE) data. Correspondence analysis (CA) has been introduced decades ago as a multivariate technique that can communicate AE contingency tables using two-dimensional plots, while quantifying the loss of information as other dimension reduction techniques such as principal components and factor analysis. Methods We propose the application of stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trial...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
International audienceAbstract Background: Drug-related iatrogenic effects are common in oncology be...
Introduction Randomised controlled trials (RCTs) provide data to help establish the harm-profile of...
BackgroundGraphical displays and data visualization are essential components of statistical analysis...
Adverse events (AEs) and concomitant medications (CMs) underreporting remains a recurrent issue in c...
Gita Thanarajasingam and colleagues' Article1 in The Lancet Oncology reports on a novel longitudinal...
International audienceDrugs are evaluated and compared during clinical trials, and the observed adve...
In clinical trials, harms (adverse events) are often reported by simply counting the number of peopl...
Objective: To improve communication of harm in RCT publications we identified researchers’ recommend...
Objective To improve communication of harm in publications of randomised controlled trials via the d...
PURPOSE: To explore medications and their administration patterns in real-world patients with breast...
Chis Ster A, Phillips R, Sauzet O, Cornelius V. Improving analysis practice of continuous adverse ev...
AIM: We investigate the concordance, in terms of favoring the same treatment arm, between clinician-...
Background: Accurate and rapid clinical decisions based on real-world evidence are essential for pat...
Adverse events following the use of medical interventions are a major source of concern for patients...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
International audienceAbstract Background: Drug-related iatrogenic effects are common in oncology be...
Introduction Randomised controlled trials (RCTs) provide data to help establish the harm-profile of...
BackgroundGraphical displays and data visualization are essential components of statistical analysis...
Adverse events (AEs) and concomitant medications (CMs) underreporting remains a recurrent issue in c...
Gita Thanarajasingam and colleagues' Article1 in The Lancet Oncology reports on a novel longitudinal...
International audienceDrugs are evaluated and compared during clinical trials, and the observed adve...
In clinical trials, harms (adverse events) are often reported by simply counting the number of peopl...
Objective: To improve communication of harm in RCT publications we identified researchers’ recommend...
Objective To improve communication of harm in publications of randomised controlled trials via the d...
PURPOSE: To explore medications and their administration patterns in real-world patients with breast...
Chis Ster A, Phillips R, Sauzet O, Cornelius V. Improving analysis practice of continuous adverse ev...
AIM: We investigate the concordance, in terms of favoring the same treatment arm, between clinician-...
Background: Accurate and rapid clinical decisions based on real-world evidence are essential for pat...
Adverse events following the use of medical interventions are a major source of concern for patients...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
International audienceAbstract Background: Drug-related iatrogenic effects are common in oncology be...
Introduction Randomised controlled trials (RCTs) provide data to help establish the harm-profile of...